Top of the hour. It's Friday night. But where do you have to go?

Hey everybody, I'm Chris Cuomo. Thank you for being here with me.

And welcome back to a bonus hour of prime time. So let's talk about treatment here. Big breakthrough, right?

A drug that may shorten the recovery time for

patients with severe COVID who are in the hospital. It's just been approved for emergency use by the

FDA. That'll make it more available. The drug's name altogether, remdesivir, Ramdesivir. Faster,

Remdesivir. now you know it.

It's the first authorized therapy drug for this virus so far.

It is our first tool in the box.

A new report from top health experts is predicting this virus could keep spreading for at least

another 18 months, maybe two years.

Perhaps 70% of the population has been infected.

And then there's the race for a vaccine. And administration official says President Trump's

goal with Operation Warp Speed is 300 million doses by January. Possible? Yes, probable. Let's discuss. Let's bring in Dr. Ashish Jha of the Harvard

Global Health Institute and Mr. Andy Slavitt, former acting administrator for centers for Medicare and

Medicaid. Gentlemen, thank you, especially on Friday night.

Thanks for having us.

Thanks, Chris.

So, Jha, are you feeling the remdesivir?

What is the level of enthusiasm we should have about this development and why?

So I am feeling enthusiasm.

Let's be very clear about what it is and what it isn't and what we know. It's not a miracle drug.

...